MacroGenics Q3 net income $16.8M on $72.8M revenue; ends lorigerlimab prostate study; secures $75M partnership payments

MACROGENICS INC

2025-Q3 EPS reported -$0.96 vs consensus -$0.50 ▼ miss (-91.4%)

Net income $16.8M ($0.27 diluted EPS) vs $56.3M ($0.90) in Q3 2024; revenue $72.8M down from $110.7M.
Discontinued lorigerlimab in prostate cancer (LORIKEET) after interim data; continues LINNET ovarian study, update by mid-2026.
Received $75M in new partnership payments: $50M from Sanofi (TZIELD milestones), $25M from Gilead (new preclinical program).
Cash $146.4M at Sep 30, expected to add $75M in Q4; runway extended into late 2027.
Three ADC programs advancing: MGC026 started Phase 1 expansion, MGC028 in Phase 1 dose escalation, MGC030 IND planned 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.